Abstract:Abstract Cervical cancer, one of the most common causes of cancer-related death among women in the world, has been linked to the presence of a particular oncoprotein that is predominantly transferred through sexual contact with an infected host. In 90% of cervical cancer deaths, a correlation has been found with the expression of the viral genome of HPV16 E6. As a result, HPV16 E6 has emerged as an optimistic therapeutic drug target for the treatment of cervical cancer. In order to develop a drug that is capable of disturbing the genome expression activity of HPV16 E6, it is imperative to identify the key chemical features of its known inhibitors. In this study, we present an investigationon identifying potential inhibitors of HPV16 E6 by utilizing pharmacophore-based virtual screening, molecular docking, ADME prediction, and molecular dynamics simulation. In the initial stage, we generated a ligand-based pharmacophore model based on the features of four known HPV16 E6 inhibitors (CA24, CA25, CA26, and CA27)via the PHASE module implanted in the Schrödinger suite. We constructedfour-point pharmacophore features, which consists of three hydrogen bond acceptors (A) and one aromatic ring (R). The common pharmacophore features further employed as a query for virtual screening against the ASINEX database via the Schrödinger suite. The pharmacophore-based virtual screening filtered out top 2000 hits, based on the fitness score. We applied the molecular docking studies for further compound filtration using Glide which provide three ligand filtering phases, namely HTVS, SP, XP. Initially, 1000 compounds were obtained from HTVS docking. Based on the glide score, they were further filtered to 500 hits by employing docking in standard precision mode. Finally, the best four hits were identified using docking in XP mode. The four compounds were then further subjected to ADME profile prediction by engaging the Qikprop module. The ADME properties of the four fell within a satisfactory range and the compounds exhibited anticipated pharmacokinetic properties. These compounds were further investigated to determine the binding stability of the protein-ligand complex at a different time scale (100 ns) by using the desmond package for a molecular dynamics simulation. These molecular dynamics simulation studies revealed that theCYS 51 and GLN 107 proteins are residues of HPV 16 E6 binding sites, and the root mean square deviation (RMSD) and root mean square fluctuations (RMSF) values for these residues were also found to be within satisfactory ranges and suggest a crucial role in enhancing the stability of the protein-ligand complex during the simulation. From these computational investigations, we concluded that the four potential compounds are appropriate for further study, and potential clinical investigation, as HPV16 E6 inhibitors.

Structure of the p53 degradation complex from HPV16

Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53

The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53

Deciphering the mechanisms of HPV E6 mutations in the destabilization of E6/E6AP/p53 complex

Ubiquitination of the HPV Oncoprotein E6 Is Critical for E6/E6AP-Mediated p53 Degradation

Structures of a human papillomavirus (HPV) E6 polypeptide bound to MAGUK proteins: mechanisms of targeting tumor suppressors by a high-risk HPV oncoprotein.

Digital RNA Sequencing of Human Epidermal Keratinocytes Carrying Human Papillomavirus Type 16 E7

Pharmacophore based virtual screening for identification of effective inhibitors to compact HPV 16 E6 a triggered cervical cancer

A Critical Role for p53 during the HPV16 Life Cycle

Structural studies of HPV oncoprotein E7 and interactions with tumor suppressor pRb

Ubiquitin-independent degradation of p53 mediated by high-risk human papillomavirus protein E6

A human papillomavirus 16 E2-TopBP1 dependent SIRT1-p300 acetylation switch regulates mitotic viral and human protein levels and activates the DNA damage response

Degradation of p53 by human Alphapapillomavirus E6 proteins shows a stronger correlation with phylogeny than oncogenicity

Structural insights into the functional mechanism of the ubiquitin ligase E6AP

Structural Basis for Recognition of the Tumor Suppressor Protein PTPN14 by the Oncoprotein E7 of Human Papillomavirus

Two Different Hpv-11e6 Fusion Proteins Trap P53 in the Cytoplasm and Induce Apoptosis

E3 Ubiquitin Ligase E6ap-Mediated Tsc2 Turnover In The Presence And Absence Of Hpv16 E6

Hpv E7 Inhibits Cell Pyroptosis By Promoting Trim21-Mediated Degradation And Ubiquitination Of The Ifi16 Inflammasome

Apoptosis Induced by an Antagonist Peptide Against HPV16 E7 in Vitro and in Vivo Via Restoration of P53.

Discovery of reactive peptide inhibitors of human papillomavirus oncoprotein E6

HPV16 E6 induces chromosomal instability due to polar chromosomes caused by E6AP-dependent degradation of the mitotic kinesin CENP-E